Semaglutide Linked to Fewer Bipolar Disorder Hospitalizations

People with bipolar disorder often have a second diagnosis with metabolic conditions among the most common. A new analysis from Sweden suggests one widely used diabetes and obesity medication may be associated with fewer psychiatric hospitalizations for these folks.

The study zeroed in on glucagon-like peptide 1 receptor agonists. This drug class includes semaglutide along with liraglutide and dulaglutide. 

The Swedish Research Study

A team drew on the National Swedish Registers to identify everyone diagnosed with bipolar disorder who used any antidiabetic medication between 2009 and 2024. They found 14,694 people. Many of these 5,200 folks used a GLP-1 receptor agonist.

The design compared each person against themselves. Investigators used a within-individual approach to measure outcomes during periods when a person was taking a GLP-1 medication against periods when they weren’t. That method reduces confounding from stable personal characteristics such as genetics, diagnosis severity or socioeconomic background.

The main outcome was psychiatric hospitalization for any reason. Secondary outcomes were psychiatric hospitalization following a bipolar disorder relapse and sick leave for psychiatric reasons.

Semaglutide Findings

Semaglutide was associated with a 21% lower risk of psychiatric hospitalization compared with non-use in the same individual, with an adjusted hazard ratio of 0.79 and a 95% confidence interval of 0.69 to 0.91. It was also linked to a 17% lower risk of inpatient hospitalization following bipolar disorder relapse, with an adjusted hazard ratio of 0.83 and a confidence interval of 0.69 to 0.99.

Liraglutide and dulaglutide weren’t associated with lower hospitalization risk. Fewer people used those medications, which can limit the analyses. But they also concluded the pattern implies this is not a class effect. Sick leave wasn’t significantly associated with any of the specific antidiabetic medications studied.

Limitations

This is an observational analysis rather than a randomized trial. It identifies an association between medication periods and hospitalization rates. It can’t establish that semaglutide reduced hospitalizations. They also don’t rule out changes in overall health engagement or other prescriptions or environmental changes or life circumstances during treatment periods.

The authors state directly that the semaglutide finding should be tested in a randomized controlled trial. No GLP-1 medication is approved for any psychiatric indication. Also note that nothing in this study supports using one in place of a mood stabilizer.

Separate work point to the other direction. One VigiBase analysis found reports of anxiety, depressed mood disorders and suicidality associated with semaglutide and eating disorders signals across all three GLP-1 medications. That doesn’t establish causation, but they’re part of the larger picture.

Co-Occurring Conditions Care Matters Here

Diabetes, obesity and bipolar disorder frequently occur together to create co-occurring conditions. The authors note they may share underlying biology. Weight gain is also a recognized side effect of several medications used to treat bipolar disorder, which can make metabolic conditions harder to manage and affect whether someone stays on treatment.

That overlap is the practical reason integrated care matters. When psychiatric care and medical care operate separately, medication interactions and metabolic side effects fall between them. Programs that treat co-occurring disorders are built to coordinate those pieces, like substance use disorders, other mental health conditions or chronic illnesses.

Treatment Options for Bipolar Disorder and Co-Occurring Conditions

Standard care for bipolar disorder centers on mood stabilizing medication managed by a psychiatrist. They often use psychotherapy approaches. Accordingly, group behavior therapy, interpersonal and social rhythm therapy and psychoeducation all appear in bipolar treatment plans often alongside family involvement.

Settings range from outpatient programs up to residential treatment centers for people who need round-the-clock structure during an acute episode.

Comprehensive Treatment Here

Folks looking for care that addresses bipolar disorder alongside a substance use disorder or a chronic medical condition might ask directly how the program handles that combination. Look into whether a psychiatrist manages medication on site, whether the program coordinates with your primary care or endocrinology team and if metabolic monitoring is part of the plan.

Our searchable directory lists mental health treatment facilities and dual diagnosis treatment programs by location and level of care. That way, you can filter for programs equipped to treat more than one condition at a time.

Feel free to also dial 800-908-4823 (Sponsored) to chat with an expert and explore local options.

Author

Quentin Blount

Content Manager

Read Bio

Quentin brings nearly a decade of experience as a writer, editor, and digital publisher to his role as Content Manager for Rehab.com. He aims to help people better understand their treatment options by creating engaging and informative content that is user-friendly, factually accurate, and optimized for search engine visibility. In his free time, Quentin enjoys the company of his friends, family, and his dog, Coop.

Editor

Peter Lee, PhD

Read Bio

Peter W.Y. Lee is a writer and historian of American history during the Cold War. His primary focus is the relationship between youth and popular culture and its impact on U.S. society during the twentieth century. He has published widely on how the public has used popular culture as a mechanism to address political and social shifts throughout time